| 1. |
|
|
| 2. |
- Björnådal, Lena, et al.
(författare)
-
Decreasing mortality in patients with rheumatoid arthrithis: results from large population based cohort in Sweden 1964-95
- 2002
-
Ingår i: Journal of Rheumatology. - 0315-162X .- 1499-2752. ; 29:5, s. 906-912
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE:To assess changes in mortality in patients with rheumatoid arthritis (RA) from 1964 to 1995.METHODS:A population based cohort of 46,917 patients with RA was identified from 1964 to 1994, using the Swedish Hospital Discharge Register, and followed until 1995 through linkage to the Cause of Death Register. Mortality was separately analyzed in each inclusion period (1964-75, 1975-84, 1985-94). The relative risk of death was estimated as standardized mortality ratio (SMR) using the Swedish population as a referenceRESULTS:All-cause mortality was increased twice the expected (SMR = 2.03, 95% CI 2.00, 2.05). Coronary artery disease was the major cause of death and mortality was increased by 80% (SMR = 1.79, 95% CI 1.75, 1.83). Females with RA aged 20-39 at first discharge had a more than 5-fold increased risk of coronary death (SMR = 5.48, 95% CI 3.45-5.71). From 1975 patients with RA had decreasing all-cause mortality. This decline was most pronounced in patients aged 40-59 at first discharge, where SMR was 2.68 (95% CI 2.45, 2.92) from 1964 to 1974 compared to SMR 1.63 (95% CI 1.37, 1.92) from 1985 to 1994.CONCLUSION:The elevated mortality rates in RA patients compared to the general population have decreased during the last 20 years, possibly due to an increased access to specialized rheumatology care. An excess risk for death in coronary artery disease was, however, present in RA patients, especially patients with early onset of disease.
|
|
| 3. |
- Glynn, Anders, et al.
(författare)
-
Regionala skillnader i kvinnors kroppsbelastning av persistenta organiskamiljöföroreningar
- 2000
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Serumhalter av PCB och klorerade bekämpningsmedel studerades bland 205 äldre kvinnorfrån 12 län efter syd- och ostkusten samt runt Vänern och Vättern. Syftet var att undersöka omdet finns regionala skillnader i kroppsbelastning av PCB och klorerade bekämpningsmedelbland äldre kvinnor i Sverige. Tio PCB-föreningar (IUPAC nr 28, 52, 101, 105, 118, 138,153, 156, 167 och 180) och 10 föreningar härrörande från klorerade bekämpningsmedelanalyserades (p,p'-DDT, o,p'-DDT, p,p'-DDE, p,p'-DDD, HCB, -HCH, -HCH, -HCH,trans-nonaklor och oxyklordan). I den statistiska analysen delades de 12 länen in i fyraregioner, Malmö-, Linköpings-, Uppsala- och Umeå-regionen. Multipel regressionsanalys, därmedelhalterna justerats för kvinnornas ålder, BMI och viktminskning under de senaste tremånaderna, visade att kroppsbelastningen av PCB 153, PCB 156, PCB 180 och HCB var13%-29% högre i Malmö-regionen än i de andra regionerna. Störst skillnad erhölls för -HCH, där kvinnor från Malmö-regionen hade nästan dubbelt så höga medelhalter än kvinnorfrån Uppsala- och Umeå-regionen. I fallet oxyklordan visade de justerade medelvärdena enmotsatt trend, dvs. halterna var högst i norr. Trots att kroppsbelastningen i några fall var högrei vissa regioner var skillnaderna inte dramatiska, vilket antyder att exponeringen för PCB ochklorerade bekämpningsmedel har varit förhållandevis jämn över landet bland den allmännabefolkningen. Resultaten visade att serumhalten av vissa PCB föreningar ökade med ökadkonsumtion av fet fisk bland kvinnorna. De regionala skillnaderna i serumhalt berodde dockinte på skillnader i konsumtion av fet fisk utan beror troligen till viss del på skillnader imiljöbelastning mellan olika regioner.
|
|
| 4. |
|
|
| 5. |
- Knight, Ann, et al.
(författare)
-
Urinary bladder cancer in Wegener's granulomatosis : risks and relation to cyclophosphamide
- 2004
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 63:10, s. 1307-1311
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE:To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.METHODS:In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified. Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified. Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk. In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.RESULTS:The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively. The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9). Treatment duration longer than 1 year was associated with an eightfold increased risk (OR = 7.7, 95% CI 0.9 to 69). The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.CONCLUSION:The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.
|
|
| 6. |
|
|
| 7. |
- Söderström, Torbjörn, et al.
(författare)
-
5alfa-reductase 2 polymorphisms as risk factors in prostate cancer
- 2002
-
Ingår i: Pharmacogenetics. - : Ovid Technologies (Wolters Kluwer Health). - 0960-314X .- 1473-561X. ; 12:4, s. 307-12
-
Tidskriftsartikel (refereegranskat)abstract
- Prostate cancer is a significant cause of death in Western countries and is under the strong influence of androgens. The steroid 5alpha-reductase 2 catalyzes the metabolism of testosterone into the more potent androgen dihydrotestosterone in the prostate gland. The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride. Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems. The L allelic variant has a lower Vmax/Km ratio than the V variant. In the A49T polymorphism, the T variant has an increased Vmax/Km ratio. We performed a population-based case-control study of the impact of the SRD5A2 V89L and A49T polymorphisms on the risk of prostate cancer. We also studied the relation between the genotypes and age at diagnosis, tumor, node, metastasis stage, differentiation grade, prostate specific antigen and heredity. The study included 175 prostate cancer patients and 159 healthy controls that were matched for age. There was an association with SRD5A2 V89L LL genotype and metastases at the time of diagnosis, OR 5.67 (95% CI 1.44-22.30) when adjusted for age, differentiation grade, T-stage and prostate specific antigen. Heterozygous prostate cancer cases that carried the SRD5A2 A49T AT genotype were significantly younger than cases that carried the AA genotype, (mean age 66 years vs 71, P = 0.038). The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk. Further studies of the V89L polymorphism may lead to better understanding of the etiology of prostate cancer metastases.
|
|
| 8. |
|
|
